Model-based treatment optimization of a novel VEGFR inhibitorRon J. Keizer; Anubha Gupta; Robert Shumaker; Jos H. Beijnen; Jan H. M. Schellens; Alwin D. R. Huitema · 2012

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820Ron J. Keizer; Miren K. Zamacona; Mendel Jansen; David Critchley; Jantien Wanders; Jos H. Beijnen; Jan H. M. Schellens; Alwin D. R. Huitema · 2009

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080Ron J. Keizer; Anubha Gupta; Melvin R. Mac Gillavry; Mendel Jansen; Jantien Wanders; Jos H. Beijnen; Jan H. M. Schellens; Mats O. Karlsson; Alwin D. R. Huitema · 2010

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)Ron J. Keizer, Anthe S. Zandvliet, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema · 2012

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studiesElena Soto; Ron J. Keizer; Iñaki F. Trocóniz; Alwin D. R. Huitema; Jos H. Beijnen; Jan H. M. Schellens; Jantien Wanders; Josep María Cendrós; Rosendo Obach; Concepción Peraire; Lena E. Friberg; Mats O. Karlsson · 2011